NEW YORK (GenomeWeb News) – Exosome Diagnostics has raised $7 million toward a goal of $8.5 million, it said in a regulatory filing on Thursday.

In an amended Form D filed with the US Securities and Exchange Commission, the New York-based molecular diagnostic firm said that the types of securities offered were in the form of debt; option, warrant, or other right to acquire another security; and security toe be acquired upon exercise of option, warrant, or other right to acquire security.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.